株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

糖尿病性黄斑浮腫:パイプライン製品の分析

Diabetic Macular Edema - Pipeline Review, H2 2017

発行 Global Markets Direct 商品コード 213121
出版日 ページ情報 英文 193 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.05円で換算しております。
Back to Top
糖尿病性黄斑浮腫:パイプライン製品の分析 Diabetic Macular Edema - Pipeline Review, H2 2017
出版日: 2017年07月18日 ページ情報: 英文 193 Pages
概要

糖尿病性黄斑浮腫(DME)は、糖尿病患者の網膜の血管が傷害されて血液中の水分や脂肪が漏れ出し、物を見る中心部の黄斑部にむくみが生じた状態(黄斑浮腫)をいいます。視界不良、飛蚊症、複視といった症状が見られ、未治療の場合は失明に至ります。素因は、年齢と糖尿病です。

当レポートでは、糖尿病性黄斑浮腫に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

糖尿病性黄斑浮腫の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

パイプライン製品の概要

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品
  • 未確認段階の製品

開発中の製品:企業別

治療薬の開発に従事している企業

治療薬の評価

  • 単独療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

パイプライン製品の最新動向

休止状態のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9563IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Macular Edema - Pipeline Review, H2 2017, provides an overview of the Diabetic Macular Edema (Metabolic Disorders) pipeline landscape.

Diabetic macular edema (DME) occurs when blood vessels in the retina of patients with diabetes begin to leak into the macula, the part of the eye responsible for detailed central vision. Common symptoms of DME are blurry vision, floaters, double vision, and eventually blindness if it goes untreated. Risk factors include age and diabetes.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Macular Edema - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Diabetic Macular Edema (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Macular Edema (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Macular Edema and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 4, 18, 6, 1, 21 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Diabetic Macular Edema (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Macular Edema (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Diabetic Macular Edema (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Diabetic Macular Edema (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Diabetic Macular Edema (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Macular Edema (Metabolic Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Diabetic Macular Edema (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Diabetic Macular Edema (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents 2
  • List of Tables 5
  • List of Figures 6
  • Introduction 7
  • Global Markets Direct Report Coverage 7
  • Diabetic Macular Edema - Overview 8
  • Diabetic Macular Edema - Therapeutics Development 9
  • Pipeline Overview 9
  • Pipeline by Companies 10
  • Pipeline by Universities/Institutes 14
  • Products under Development by Companies 15
  • Products under Development by Universities/Institutes 18
  • Diabetic Macular Edema - Therapeutics Assessment 19
  • Assessment by Target 19
  • Assessment by Mechanism of Action 22
  • Assessment by Route of Administration 25
  • Assessment by Molecule Type 27
  • Diabetic Macular Edema - Companies Involved in Therapeutics Development 29
  • Aciont Inc 29
  • ActiveSite Pharmaceuticals Inc 29
  • Acucela Inc 30
  • Aerie Pharmaceuticals Inc 30
  • Aerpio Therapeutics Inc 31
  • Alcon Laboratories Inc 31
  • Allergan Plc 32
  • Ampio Pharmaceuticals Inc 32
  • Araim Pharmaceuticals Inc 33
  • Boehringer Ingelheim GmbH 33
  • Cell Medica Ltd 34
  • Chengdu Kanghong Pharmaceuticals Group Co Ltd 34
  • Clearside BioMedical Inc 35
  • Coherus BioSciences Inc 35
  • EyeGate Pharmaceuticals Inc 36
  • F. Hoffmann-La Roche Ltd 36
  • Formycon AG 37
  • Genmab A/S 37
  • GlaxoSmithKline Plc 38
  • Icon Bioscience Inc 38
  • Kala Pharmaceuticals Inc 39
  • Kalvista Pharmaceuticals Inc 39
  • Kowa Company Ltd 40
  • Lupin Ltd 40
  • Mabion SA 41
  • Ocular Therapeutix Inc 41
  • Oculis ehf 42
  • Ohr Pharmaceutical Inc 42
  • Pfizer Inc 43
  • pSivida Corp 43
  • Regeneron Pharmaceuticals Inc 44
  • SciFluor Life Sciences LLC 44
  • Senju Pharmaceutical Co Ltd 45
  • Stealth BioTherapeutics Inc 45
  • ThromboGenics NV 46
  • Verseon Corp 46
  • Xbrane Biopharma AB 47
  • Diabetic Macular Edema - Drug Profiles 48
  • (aflibercept + nesvacumab) - Drug Profile 48
  • abicipar pegol - Drug Profile 50
  • ACU-6151 - Drug Profile 53
  • ACX-107 - Drug Profile 54
  • aflibercept biosimilar - Drug Profile 55
  • aflibercept biosimilar - Drug Profile 56
  • AKB-9778 - Drug Profile 57
  • ALG-1001 - Drug Profile 62
  • Antibodies to Inhibit Hemopexin for Diabetic Macular Edema - Drug Profile 66
  • AR-13154 - Drug Profile 67
  • ARP-1536 - Drug Profile 68
  • ASPPDC-010 - Drug Profile 69
  • BI-1026706 - Drug Profile 70
  • Biologics to Inhibit Semaphorin 3A and VEGF for Diabetic Complications - Drug Profile 72
  • brolucizumab - Drug Profile 73
  • bromfenac sodium - Drug Profile 76
  • cibinetide - Drug Profile 78
  • conbercept - Drug Profile 81
  • danazol - Drug Profile 83
  • darapladib - Drug Profile 87
  • dexamethasone acetate - Drug Profile 90
  • dexamethasone acetate - Drug Profile 96
  • dexamethasone dipropionate XR - Drug Profile 98
  • difluprednate - Drug Profile 99
  • Drug for Diabetic Macular Edema - Drug Profile 100
  • EBI-031 - Drug Profile 101
  • elamipretide - Drug Profile 102
  • fluocinolone acetonide SR - Drug Profile 110
  • HO-10 - Drug Profile 119
  • HPV-19 - Drug Profile 120
  • JDE-006 - Drug Profile 121
  • KPI-285 - Drug Profile 122
  • KVD-001 - Drug Profile 123
  • LKA-651 - Drug Profile 125
  • NM-108 - Drug Profile 126
  • OCX-063 - Drug Profile 127
  • OTX-TKI - Drug Profile 128
  • PF-655 - Drug Profile 130
  • Protein to Inhibit VEGF for Ophthalmology - Drug Profile 133
  • ranibizumab biosimilar - Drug Profile 134
  • ranibizumab biosimilar - Drug Profile 135
  • ranibizumab biosimilar - Drug Profile 136
  • ranibizumab biosimilar - Drug Profile 138
  • ranibizumab biosimilar - Drug Profile 139
  • RG-7716 - Drug Profile 140
  • ripasudil - Drug Profile 142
  • SF-0166 - Drug Profile 144
  • Small Molecule for Diabetic Macular Edema - Drug Profile 146
  • Small Molecule to Inhibit LP-PLA2 for Diabetic Macular Edema - Drug Profile 147
  • Small Molecules to Inhibit Plasma Kallikrein for Diabetic Macular Edema - Drug Profile 148
  • squalamine lactate - Drug Profile 149
  • teprotumumab - Drug Profile 157
  • THR-149 - Drug Profile 160
  • THR-317 - Drug Profile 161
  • triamcinolone acetonide - Drug Profile 164
  • triamcinolone acetonide - Drug Profile 165
  • VA-999272 - Drug Profile 172
  • Diabetic Macular Edema - Dormant Projects 173
  • Diabetic Macular Edema - Discontinued Products 175
  • Diabetic Macular Edema - Product Development Milestones 176
  • Featured News & Press Releases 176
  • Appendix 188
  • Methodology 188
  • Coverage 188
  • Secondary Research 188
  • Primary Research 188
  • Expert Panel Validation 188
  • Contact Us 188
  • Disclaimer 189

List of Tables

  • Number of Products under Development for Diabetic Macular Edema, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Diabetic Macular Edema - Pipeline by Aciont Inc, H2 2017
  • Diabetic Macular Edema - Pipeline by ActiveSite Pharmaceuticals Inc, H2 2017
  • Diabetic Macular Edema - Pipeline by Acucela Inc, H2 2017
  • Diabetic Macular Edema - Pipeline by Aerie Pharmaceuticals Inc, H2 2017
  • Diabetic Macular Edema - Pipeline by Aerpio Therapeutics Inc, H2 2017
  • Diabetic Macular Edema - Pipeline by Alcon Laboratories Inc, H2 2017
  • Diabetic Macular Edema - Pipeline by Allergan Plc, H2 2017
  • Diabetic Macular Edema - Pipeline by Ampio Pharmaceuticals Inc, H2 2017
  • Diabetic Macular Edema - Pipeline by Araim Pharmaceuticals Inc, H2 2017
  • Diabetic Macular Edema - Pipeline by Boehringer Ingelheim GmbH, H2 2017
  • Diabetic Macular Edema - Pipeline by Cell Medica Ltd, H2 2017
  • Diabetic Macular Edema - Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, H2 2017
  • Diabetic Macular Edema - Pipeline by Clearside BioMedical Inc, H2 2017
  • Diabetic Macular Edema - Pipeline by Coherus BioSciences Inc, H2 2017
  • Diabetic Macular Edema - Pipeline by EyeGate Pharmaceuticals Inc, H2 2017
  • Diabetic Macular Edema - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
  • Diabetic Macular Edema - Pipeline by Formycon AG, H2 2017
  • Diabetic Macular Edema - Pipeline by Genmab A/S, H2 2017
  • Diabetic Macular Edema - Pipeline by GlaxoSmithKline Plc, H2 2017
  • Diabetic Macular Edema - Pipeline by Icon Bioscience Inc, H2 2017
  • Diabetic Macular Edema - Pipeline by Kala Pharmaceuticals Inc, H2 2017
  • Diabetic Macular Edema - Pipeline by Kalvista Pharmaceuticals Inc, H2 2017
  • Diabetic Macular Edema - Pipeline by Kowa Company Ltd, H2 2017
  • Diabetic Macular Edema - Pipeline by Lupin Ltd, H2 2017
  • Diabetic Macular Edema - Pipeline by Mabion SA, H2 2017
  • Diabetic Macular Edema - Pipeline by Ocular Therapeutix Inc, H2 2017
  • Diabetic Macular Edema - Pipeline by Oculis ehf, H2 2017
  • Diabetic Macular Edema - Pipeline by Ohr Pharmaceutical Inc, H2 2017
  • Diabetic Macular Edema - Pipeline by Pfizer Inc, H2 2017
  • Diabetic Macular Edema - Pipeline by pSivida Corp, H2 2017
  • Diabetic Macular Edema - Pipeline by Regeneron Pharmaceuticals Inc, H2 2017
  • Diabetic Macular Edema - Pipeline by SciFluor Life Sciences LLC, H2 2017
  • Diabetic Macular Edema - Pipeline by Senju Pharmaceutical Co Ltd, H2 2017
  • Diabetic Macular Edema - Pipeline by Stealth BioTherapeutics Inc, H2 2017
  • Diabetic Macular Edema - Pipeline by ThromboGenics NV, H2 2017
  • Diabetic Macular Edema - Pipeline by Verseon Corp, H2 2017
  • Diabetic Macular Edema - Pipeline by Xbrane Biopharma AB, H2 2017
  • Diabetic Macular Edema - Dormant Projects, H2 2017
  • Diabetic Macular Edema - Dormant Projects, H2 2017 (Contd..1), H2 2017
  • Diabetic Macular Edema - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Diabetic Macular Edema, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Targets, H2 2017
  • Number of Products by Stage and Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Top 10 Molecule Types, H2 2017
  • Number of Products by Stage and Top 10 Molecule Types, H2 2017
Back to Top